10 - 16 October 2020
These are links to recent news stories about multiple sclerosis that may be of interest to people affected by MS in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter, or regular email alerts.
Siponimod approved for SPMS
Siponimod (Mayzent), a drug for active secondary progressive MS that reduces the number of relapses and slows the build up of disability, has been approved for use on the NHS in England, Wales and Scotland.
MS differences by gender and disease type
Women with MS are more likely to be affected by pain, depression and cognitive symptoms than men, according to research based on the German MS Register. Other symptoms are more associated with type of MS than gender - visual and sensory problems were more common in relapsing MS and problems with walking, spasticity and ataxia occurred more often in progressive MS
MS Trust link: MS symptoms
Factors affecting MS and employment explored
The risk of stopping working is high in MS, particularly in the first years after diagnosis, according to a US study. People at risk of unemployment were more likely to have a progressive MS, fatigue, sleep problems, pain, anxiety and depression. They were also more likely to feel they lacked control of their situation than people with MS who remained in work
Source: MS News Today
MS Trust link: Working life
MS in the Media
27 Nov 2020 - 00:00
- Depression affects multitasking in MS
- Benefits process in Scotland
- Cancer risks and multiple sclerosis
- Gut immune cells and relapses
MS in the Media
20 Nov 2020 - 00:00
- New study for advanced MS
- Campaign for fair benefits during the pandemic
- Stem cells compared to Lemtrada
- DMD use and finances
David Martin appointed Chair of the Neurological Alliance
18 Nov 2020 - 00:00
The MS Trust is delighted to announce that CEO David Martin, has been voted in as Chair of the Neurological Alliance.